title: Primed fibroblasts and exogenous decorin: potential treatments for subacute vocal fold scar.
abstract: OBJECTIVE
  To investigate hepatocyte growth factor (HGF) primed fibroblasts and decorin application on skin and vocal fold fibroblasts in vitro and in vivo in rabbit vocal fold scar model.
  
  
  METHODS
  Vocal fold and skin fibroblasts underwent five in vitro treatment conditions: control, epidermal growth factor, HGF, both decorin and HGF, and decorin alone. Hyaluronic acid and collagen enzyme-linked immunosorbent assays were performed. In vivo, 12 rabbits underwent unilateral vocal fold stripping. Injured vocal folds were then injected with skin fibroblasts, HGF, HGF-primed fibroblasts and decorin, or decorin. Outcomes included histologic and lamina propria height analyses.
  
  
  RESULTS
  In vitro, HGF increased hyaluronic acid synthesis in vocal fold fibroblasts (P<0.001). HGF and decorin treatment diminished collagen secretion (P<0.01). In vivo, histologic findings indicated minimal difference in collagen amount between treatment groups.
  
  
  CONCLUSIONS
  HGF and decorin together may decrease collagen production by skin and vocal fold fibroblasts. Fibroblast transplantation into scarred vocal folds has equivocal benefit.
authors.affiliation: University of Pittsburgh Voice Center, Department of Otolaryngology, PA 15213, USA. krishnpd@upmc.edu
authors.forename: Priya
authors.initials: P
authors.lastname: Krishna
authors.forename: Clark A
authors.initials: CA
authors.lastname: Rosen
authors.forename: Ryan C
authors.initials: RC
authors.lastname: Branski
authors.forename: Alan
authors.initials: A
authors.lastname: Wells
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Hebda
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D002921:Cicatrix / Q000188:drug therapy*; D024042:Collagen Type I / Q000187:drug effects* / Q000378:metabolism; D058575:Decorin; D004195:Disease Models, Animal; D004815:Epidermal Growth Factor / Q000494:pharmacology* / Q000627:therapeutic use; D016326:Extracellular Matrix Proteins / Q000494:pharmacology* / Q000627:therapeutic use; D005260:Female; D005347:Fibroblasts; D017228:Hepatocyte Growth Factor / Q000494:pharmacology* / Q000627:therapeutic use; D006820:Hyaluronic Acid / Q000378:metabolism; D011509:Proteoglycans / Q000494:pharmacology* / Q000627:therapeutic use; D011817:Rabbits; D012867:Skin / Q000473:pathology; D014827:Vocal Cords / Q000473:pathology
chemical_list: D024042:Collagen Type I; D058575:Decorin; D016326:Extracellular Matrix Proteins; D011509:Proteoglycans; D004815:Epidermal Growth Factor; D017228:Hepatocyte Growth Factor; D006820:Hyaluronic Acid